Browse OSR2

Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain -
Function

-

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0002062 chondrocyte differentiation
GO:0007369 gastrulation
GO:0007423 sensory organ development
GO:0010470 regulation of gastrulation
GO:0030278 regulation of ossification
GO:0030282 bone mineralization
GO:0030326 embryonic limb morphogenesis
GO:0030500 regulation of bone mineralization
GO:0030501 positive regulation of bone mineralization
GO:0031214 biomineral tissue development
GO:0033687 osteoblast proliferation
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035115 embryonic forelimb morphogenesis
GO:0035116 embryonic hindlimb morphogenesis
GO:0035136 forelimb morphogenesis
GO:0035137 hindlimb morphogenesis
GO:0036022 limb joint morphogenesis
GO:0036023 embryonic skeletal limb joint morphogenesis
GO:0040019 positive regulation of embryonic development
GO:0042471 ear morphogenesis
GO:0042474 middle ear morphogenesis
GO:0042476 odontogenesis
GO:0042733 embryonic digit morphogenesis
GO:0043010 camera-type eye development
GO:0043583 ear development
GO:0045778 positive regulation of ossification
GO:0045995 regulation of embryonic development
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048736 appendage development
GO:0048793 pronephros development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0051216 cartilage development
GO:0060021 palate development
GO:0060173 limb development
GO:0060272 embryonic skeletal joint morphogenesis
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0061029 eyelid development in camera-type eye
GO:0061448 connective tissue development
GO:0070167 regulation of biomineral tissue development
GO:0070169 positive regulation of biomineral tissue development
GO:0072001 renal system development
GO:0072498 embryonic skeletal joint development
GO:0090596 sensory organ morphogenesis
GO:2000543 positive regulation of gastrulation
Molecular Function GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OSR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OSR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OSR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8610.0431
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3240.126
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5150.434
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4880.363
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7090.657
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2090.916
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.080.914
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6650.527
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.430.701
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0060.995
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1740.279
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1740.373
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OSR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OSR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OSR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OSR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OSR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OSR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OSR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOSR2
Nameodd-skipped related transciption factor 2
Aliases FLJ90037; odd-skipped related 2 (Drosophila); odd-skipped related 2; Protein odd-skipped-related 2
Chromosomal Location8q22.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OSR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.